Breaking News Instant updates and real-time market news.

CLVS

Clovis

$16.60

-0.12 (-0.72%)

17:42
10/30/18
10/30
17:42
10/30/18
17:42

Clovis plunges over 20% after reporting larger Q3 loss than expected

"As discussed last quarter, growth remains challenging in the second-line maintenance ovarian cancer setting, but we have efforts underway to address this and we are aggressively moving forward to grow this market and grow our share of this market. In addition, our development team continues to make significant progress in moving Rubraca beyond its initial ovarian cancer indications. In particular, we were very pleased with the data from the TRITON studies presented at ESMO and at the Prostate Cancer Foundation Scientific Retreat, which also served as the basis for Breakthrough Therapy designation, and we are committed to developing Rubraca in the prostate setting as rapidly as possible to support men with this difficult-to-treat disease," said CEO Patrick Mahaffy. Shares of Clovis are down 20.29% or $3.37 per share to $13.24 in after-hours trading.

  • 30

    Oct

  • 12

    Nov

CLVS Clovis
$16.60

-0.12 (-0.72%)

10/19/18
RHCO
10/19/18
NO CHANGE
Target $90
RHCO
Buy
SunTrust impressed by prostate cancer data from Clovis
The initial Triton2 data this morning from Clovis Oncology show an "impressive" objective response rate at 44%, which is at the higher end of expectations, SunTrust analyst Peter Lawson tells investors in a research note. The analyst notes the 44% is above his previewed ORR of greater than 20% and that management previously mentioned that a 20%-25% rate would be impressive. Lawson finds the supportive confirmed prostate specific antigen response rate of 51% as impressive also. He reiterates a Buy rating on Clovis shares with a $90 price target. The stock in morning trading is down 2%, or 67c, to $29.29.
10/19/18
PIPR
10/19/18
NO CHANGE
PIPR
Neutral
Clovis data 'solid,' but others likely to follow, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro believes Clovis Oncology reported "solid" initial data from the Triton2 study evaluating Rubraca in HRD+ metastatic castrate resistant prostate cancer patients. In the subset of BRCA+ patients, Rubraca reported a 44% objective response rate and 51.1% confirmed prostate specific antigen response rate, Catanzaro tells investors in a research note. The analyst says that while this is "definitely a positive outcome" for Rubraca, he expects "this opportunity to become very competitive in the near term." He feels Rubraca is likely not the last PARP to show these response rates and keeps a Neutral rating on Clovis shares.
10/18/18
PIPR
10/18/18
INITIATION
Target $33
PIPR
Neutral
Clovis assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Clovis Oncology with a Neutral rating and $33 price target. The analyst believes the shares are fairly valued based on Rubraca's long-term potential across the ovarian cancer treatment landscape. He also has concerns with near- and long-term consensus estimates for the drug.
10/02/18
JPMS
10/02/18
NO CHANGE
JPMS
Overweight
JPMorgan increasingly confident in Clovis Oncology's rucaparib
JPMorgan analyst Cory Kasimov is encouraged by Clovis Oncology's announcement this morning that rucaparib received breakthrough designation from the FDA for the third line treatment of patients with BRCA mutated metastatic castrate-resistant prostate cancer on the basis of data from the Triton-2 study. The analyst says the news further increases his confidence in the potential for rucaparib to produce response rates that are meaningfully better than currently available options. His model implies $9 per share for prostate, assuming a 55% probability of success and $450M in peak unadjusted sales. Kasimov keeps an Overweight rating on Clovis, which is up 11%, or $3.33, to $32.47 in morning trading.

TODAY'S FREE FLY STORIES

AMRN

Amarin

$17.73

0.31 (1.78%)

, NVS

Novartis

$90.51

(0.00%)

10:05
02/22/19
02/22
10:05
02/22/19
10:05
Rumors
Rumor moving shares of Amarin, Novartis »

Amarin early strength…

AMRN

Amarin

$17.73

0.31 (1.78%)

NVS

Novartis

$90.51

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 11

    Mar

  • 12

    Mar

  • 19

    Mar

INNT

Innovate Biopharmaceuticals

$1.99

-0.09 (-4.33%)

10:02
02/22/19
02/22
10:02
02/22/19
10:02
Hot Stocks
Innovate CEO Christopher Prior to depart, Sandeep Laumas to succeed »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$19.52

0.12 (0.62%)

10:01
02/22/19
02/22
10:01
02/22/19
10:01
Hot Stocks
Breaking Hot Stocks news story on PG&E »

PG&E trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$7.65

0.63 (8.97%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Options
Pitney Bowes calls seeing interest as shares rally 7% »

Pitney Bowes calls seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    Mar

LTN

Union Acquisition Corp

$7.33

(0.00%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Union Acquisition Corp falls -13.5% »

Union Acquisition Corp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ASPN

Aspen Aerogels

$3.25

-0.35 (-9.72%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Aspen Aerogels falls -9.4% »

Aspen Aerogels is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$8.66

-4.8 (-35.66%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Diplomat Pharmacy falls -35.4% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

SWM

Schweitzer-Mauduit

$39.98

5.29 (15.25%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Schweitzer-Mauduit rises 11.8% »

Schweitzer-Mauduit is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

BYD

Boyd Gaming

$30.95

2.67 (9.44%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Boyd Gaming rises 9.6% »

Boyd Gaming is up 9.6%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$149.00

31.86 (27.20%)

10:00
02/22/19
02/22
10:00
02/22/19
10:00
Hot Stocks
Wayfair rises 27.1% »

Wayfair is up 27.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

10:00
02/22/19
02/22
10:00
02/22/19
10:00
General news
Treasury Action: yields are drifting lower, even as Wall Street opens in the green »

Treasury Action: yields…

10:00
02/22/19
02/22
10:00
02/22/19
10:00
General news
Breaking General news story  »

New York Federal Reserve…

10:00
02/22/19
02/22
10:00
02/22/19
10:00
General news
Breaking General news story  »

San Francisco Federal…

MORN

Morningstar

$126.83

-0.37 (-0.29%)

09:57
02/22/19
02/22
09:57
02/22/19
09:57
Earnings
Morningstar drops after admitting late 2018 market downturn hurt asset growth »

Morningstar last night…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLPH

Delphi Technologies

$23.30

1.6 (7.37%)

, INTU

Intuit

$238.70

3.85 (1.64%)

09:55
02/22/19
02/22
09:55
02/22/19
09:55
Options
Early notable gainers among liquid option names on February 22nd »

Notable gainers among…

DLPH

Delphi Technologies

$23.30

1.6 (7.37%)

INTU

Intuit

$238.70

3.85 (1.64%)

EQT

EQT Corporation

$19.51

0.48 (2.52%)

CXO

Concho Resources

$106.07

2.38 (2.30%)

PXD

Pioneer Natural

$140.11

3.9 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 22

    May

  • 28

    May

ISRG

Intuitive Surgical

$555.58

5.59 (1.02%)

09:53
02/22/19
02/22
09:53
02/22/19
09:53
Technical Analysis
Technical Take: Intuitive Surgical has a large active bullish pattern »

On a 5-year weekly chart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$24.76

2 (8.79%)

09:51
02/22/19
02/22
09:51
02/22/19
09:51
Upgrade
iQIYI rating change  »

iQIYI upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

MORN

Morningstar

$127.20

(0.00%)

09:50
02/22/19
02/22
09:50
02/22/19
09:50
Hot Stocks
Breaking Hot Stocks news story on Morningstar »

Morningstar trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$1.28

(0.00%)

09:50
02/22/19
02/22
09:50
02/22/19
09:50
Hot Stocks
Breaking Hot Stocks news story on Trillium Therapeutics »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

W

Wayfair

$143.50

26.36 (22.50%)

09:49
02/22/19
02/22
09:49
02/22/19
09:49
Recommendations
Wayfair analyst commentary  »

Wayfair's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    Mar

ASTE

Astec

$39.41

(0.00%)

, TEX

Terex

$35.65

0.06 (0.17%)

09:48
02/22/19
02/22
09:48
02/22/19
09:48
Recommendations
Astec ticks higher after Baird discusses possible takeover by Terex »

Terex (TEX) delaying its…

ASTE

Astec

$39.41

(0.00%)

TEX

Terex

$35.65

0.06 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$43.05

-4.22 (-8.93%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Nevro falls -9.2% »

Nevro is down -9.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPN

Aspen Aerogels

$3.60

(0.00%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Aspen Aerogels falls -12.8% »

Aspen Aerogels is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$8.86

-4.6 (-34.18%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
Diplomat Pharmacy falls -34.1% »

Diplomat Pharmacy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

PAGS

PagSeguro Digital

$25.10

2.24 (9.80%)

09:47
02/22/19
02/22
09:47
02/22/19
09:47
Hot Stocks
PagSeguro Digital rises 11.1% »

PagSeguro Digital is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.